FUROSCIX’s Label Update Is A Buying Signal For scPharmaceuticals

by Biotech Newsroom


Word Count: 2,490 words, Reading Time: 12 minutes

scPharmaceuticals SCPH 0.00%↑ is a commercial-stage biopharma marketing the product FUROSCIX. FUROSCIX is a subcutaneous (“sc” hence the company name…) formulation of furosemide, a loop diuretic first approved in 1982. While the molecular entity may be old hat, the pharmacokinetics are actually pretty impressive. scPharmaceuticals is the first company who has been able to essentially replicate the pharmacokinetics and diuresis of two IV push injections of furosemide in one…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC